Herbal Monograph

Saffron

Crocus sativus L.

Iridaceae

Class 1 Anxiolytic Nootropic Antioxidant Anti-inflammatory

Premier neurotropic spice with strong clinical evidence for depression, anxie...

Overview

Plant Description

A small, autumn-flowering perennial geophyte growing 10-30 cm tall from a globose corm (3-5 cm diameter). Leaves are grass-like, narrow (1-3 mm wide), dark green with a central white stripe, appearing simultaneously with or shortly after the flowers. Each corm produces 1-4 flowers with six pale lilac to mauve-purple tepals. The style divides into three vivid crimson stigmas (25-30 mm long), which droop over the perianth -- these are the saffron spice. Stamens are three, with yellow anthers. The plant is a sterile autotriploid (2n = 3x = 24) incapable of producing viable seed and must be propagated vegetatively by daughter corms.

Habitat

Cultivated crop; does not exist in the wild. Requires Mediterranean or semi-arid continental climate with hot, dry summers and cool winters. Grows best at 600-1500 m elevation in well-drained, calcareous to neutral soils (pH 6-8). Requires a distinct summer dormancy period. Not frost-hardy below approximately -10 degrees C during winter dormancy. Flowering occurs in autumn (October-November in the Northern Hemisphere) and is triggered by declining temperatures.

Distribution

Cultivated primarily in Iran (>90% of world production, especially Khorasan province), followed by India (Kashmir), Greece (Kozani), Spain (La Mancha), Morocco (Taliouine), and Afghanistan (Herat). Small-scale cultivation in Italy (Sardinia, Abruzzo), Azerbaijan, and recently in the United States (Vermont, Pennsylvania). Iran dominates global production with approximately 300-400 tonnes annually.

Parts Used

Stigma (dried)

Preferred: Standardized extract (capsule) or dried stigma (infusion)

The three crimson stigmas of the flower, harvested and dried, constitute the saffron spice. This is the primary medicinal part used in virtually all clinical research and pharmacopeial monographs. Contains the key apocarotenoids (crocin, crocetin), the bitter glycoside picrocrocin, and the aromatic aldehyde safranal. Standardized extracts for clinical use are derived from the dried stigma.

Petal (tepal)

Preferred: Infusion (traditional)

The purple tepals are a byproduct of saffron production and are traditionally used in Iranian and Kashmiri folk medicine as a mild sedative tea. Recent research has identified flavonoids (kaempferol, quercetin) and anthocyanins in the petals. Less extensively studied than the stigma but gaining research interest as a sustainable use of floral waste. Not included in official pharmacopeial monographs.

Key Constituents

Apocarotenoids (stigma)

Crocin (crocin-1 / trans-crocin-4 / alpha-crocin) Major pigment; 6-16% of dried stigma weight (varies by origin and grade)
Crocetin Aglycone released from crocin hydrolysis; minor as free form in dried stigma
Picrocrocin 1-13% of dried stigma weight
Safranal 0.001-0.006% of dried stigma (highly volatile)

The apocarotenoids are the principal pharmacologically active compounds in saffron. Crocin and crocetin are responsible for the antidepressant, neuroprotective, and antioxidant effects demonstrated in clinical trials. They modulate multiple neurotransmitter systems (serotonergic, dopaminergic, glutamatergic) and reduce neuroinflammation via NF-kB inhibition. Safranal contributes anxiolytic and anticonvulsant properties through GABAergic modulation. Picrocrocin provides the bitter digestive stimulant action. Together, these compounds establish saffron as a multi-target neurotropic herb.

Flavonoids (stigma and petal)

Kaempferol and kaempferol glycosides (including kaempferol-3-O-sophoroside / PCS-1) Present in both stigma and petals
Quercetin Minor flavonoid in stigma; more abundant in petals

The flavonoid fraction contributes to saffron's overall antioxidant and anti-inflammatory activity. Kaempferol glycosides, particularly PCS-1, may contribute to the antidepressant effect via AMPK activation, complementing the apocarotenoid-mediated neurotransmitter modulation.

Vitamins and minerals (stigma)

Riboflavin (vitamin B2) ~0.1 mg per gram of dried saffron
Minerals (manganese, copper, iron, magnesium, potassium) Trace to moderate amounts

At the small doses used medicinally (20-30 mg/day), the vitamin and mineral content of saffron is nutritionally negligible. These constituents are more relevant when saffron is used as a culinary spice in larger quantities.

Herbal Actions

Anxiolytic (primary)

Reduces anxiety

Saffron extract (30 mg/day) demonstrated significant anxiolytic effects in multiple RCTs. Safranal acts as a GABA-A receptor agonist. Crocin modulates serotonergic neurotransmission. A systematic review of RCTs (Han et al. 2024) found consistent anxiolytic effects across multiple trials. The proprietary extract affron (standardized saffron) reduced negative mood and anxiety symptoms in a 128-participant RCT (Kell et al. 2017).

[4, 7, 8]
Nootropic (primary)

Enhances cognitive function, memory, and mental performance

Saffron and its active constituents (crocin, crocetin) demonstrate neuroprotective and cognitive-enhancing effects. Systematic review of RCTs found saffron improved cognitive function in patients with mild cognitive impairment and Alzheimer's disease, with efficacy comparable to donepezil (Han et al. 2024). Mechanisms include anti-amyloid activity, acetylcholinesterase inhibition, anti-neuroinflammation, and BDNF modulation. Saffron 30 mg/day was comparable to methylphenidate for ADHD symptoms in a pediatric RCT (Baziar et al. 2019).

[6, 8, 20]
Antioxidant (primary)

Prevents or slows oxidative damage to cells

Crocin and crocetin are potent radical scavengers that protect against oxidative damage in neural, hepatic, and cardiovascular tissues. Saffron supplementation significantly increased total antioxidant capacity (TAC) and reduced malondialdehyde (MDA, a marker of lipid peroxidation) in clinical studies. The apocarotenoid pigments quench reactive oxygen species (ROS) and upregulate endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase).

[11, 13]
Anti-inflammatory (secondary)

Reduces inflammation

Crocin and crocetin inhibit NF-kB signaling, reduce TNF-alpha, IL-1beta, and IL-6 in both in vitro and animal models. Safranal alleviated OVA-induced asthma and inhibited mast cell activation in animal models (Lertnimitphun et al. 2021). Clinical evidence for anti-inflammatory effects in humans is still emerging but supported by reductions in inflammatory markers (CRP, MDA) in supplementation studies.

[16, 17]
Immunomodulating (secondary)

Modulates and balances immune function

Saffron and its constituents modulate both innate and adaptive immune responses. Crocin and safranal shift the Th1/Th2 cytokine balance, enhance natural killer cell activity, and modulate macrophage function. A comprehensive review (Khazdair et al. 2021) compared the immunomodulatory effects of saffron with Nigella sativa, finding that saffron constituents regulate T-cell differentiation and reduce autoimmune-related inflammation.

[17, 18]
Cardiotonic (secondary)

Strengthens and tones the heart muscle

Crocetin has demonstrated anti-atherosclerotic effects by inhibiting LDL oxidation and reducing serum cholesterol in animal studies. Saffron has shown modest antihypertensive effects in preclinical models. Clinical evidence for cardiovascular effects in humans remains preliminary but consistent with the strong antioxidant profile.

[13]
Bitter (mild)

Stimulates digestive secretions via bitter taste receptors

Picrocrocin gives saffron its characteristic bitter taste. As with other bitter compounds, it may mildly stimulate digestive secretions via bitter taste receptor (T2R) activation. However, saffron is not traditionally classified as a primary bitter herb, and the bitter action is secondary to its neurotropic properties.

[11]

Therapeutic Indications

Nervous System

well established

Mild to moderate depression

Meta-analysis of RCTs (Toth et al. 2019) confirmed saffron extract 30 mg/day is significantly more effective than placebo for mild to moderate depression. Multiple head-to-head RCTs found saffron comparable in efficacy to fluoxetine 20 mg/day and imipramine 100 mg/day with fewer side effects. Lopresti & Drummond (2014) systematic review documented consistent antidepressant effects across 6 RCTs with standardized 30 mg/day dosing over 6-8 weeks. Dai et al. (2020) meta-analysis reaffirmed safety and efficacy. Mechanisms include serotonin reuptake inhibition, BDNF modulation, HPA axis regulation, and anti-neuroinflammatory effects.

[3, 4, 5]
supported

Generalized anxiety and stress-related mood disturbance

Kell et al. (2017) found that affron (standardized saffron extract, 28 mg/day) significantly reduced negative mood and symptoms related to stress and anxiety in a 128-participant RCT over 4 weeks. Han et al. (2024) systematic review found consistent anxiolytic effects across multiple RCTs. Safranal's GABA-A receptor agonism provides a pharmacological basis for the anxiolytic activity.

[7, 8]
supported

Attention-deficit/hyperactivity disorder (ADHD) in children

Baziar et al. (2019) conducted a 6-week randomized double-blind pilot study comparing saffron capsules (20-30 mg/day) with methylphenidate (20-30 mg/day) in 54 children aged 6-17 with ADHD. Saffron showed comparable efficacy on the Teacher and Parent ADHD Rating Scale with no significant between-group differences. Both groups improved significantly from baseline. Saffron was well-tolerated with fewer appetite-related side effects. Further large-scale trials are needed to confirm these results.

[6, 8]
supported

Mild cognitive impairment and Alzheimer's disease (supportive)

Saffron 30 mg/day for 16-22 weeks showed comparable efficacy to donepezil 10 mg for mild-to-moderate Alzheimer's disease in two RCTs. Systematic review (Han et al. 2024) concluded saffron may benefit cognitive function through multiple mechanisms: anti-amyloid beta aggregation, acetylcholinesterase inhibition, BDNF enhancement, and reduction of neuroinflammation. A recent narrative review (Kehtari et al. 2025) reaffirmed saffron's potential from mood to memory across the neurocognitive spectrum.

[8, 10, 20]
preliminary

Sleep disturbances

Systematic review (Han et al. 2024) identified emerging evidence that saffron may improve sleep quality parameters. The GABA-A agonist activity of safranal provides a plausible mechanism. Clinical evidence remains limited with few dedicated sleep trials.

[8, 22]

Cardiovascular System

preliminary

Dyslipidemia and atherosclerosis prevention (supportive)

Crocetin inhibits LDL oxidation and has shown anti-atherosclerotic effects in animal models. Some clinical studies report modest improvements in lipid profiles with saffron supplementation. A review of the anti-diabetic potential of saffron (Sani et al. 2022) noted improvements in glycemic and lipid parameters. Evidence is not yet sufficient for saffron to be recommended as a primary intervention for dyslipidemia.

[13, 14]

Endocrine System

preliminary

Metabolic syndrome and type 2 diabetes support

Crocin has demonstrated hypoglycemic and insulin-sensitizing effects in animal and some human studies. A review (Sani et al. 2022) summarized evidence that saffron reduces fasting blood glucose, HbA1c, and insulin resistance markers in diabetic models. Clinical evidence in humans is still limited and saffron should not replace conventional diabetes management.

[14]
supported

Premenstrual syndrome (PMS)

Two RCTs found saffron 30 mg/day effective for relieving PMS symptoms (both physical and psychological) compared to placebo over 2 menstrual cycles. Saffron's serotonergic modulation likely mediates the effect on mood-related PMS symptoms.

[4]

Skin / Integumentary

supported

Age-related macular degeneration (supportive)

A systematic review and meta-analysis (Shamabadi et al. 2024) assessed saffron for age-related macular degeneration (ARMD), finding that saffron supplementation (typically 20-30 mg/day) showed promising neuroprotective and antioxidant effects that may delay disease progression. Crocin and crocetin protect retinal pigment epithelium from oxidative damage. Multiple small clinical trials have reported improvements in macular function and visual acuity.

[9]

Immune System

preliminary

Immune dysregulation and autoimmune conditions (supportive)

Saffron demonstrates immunomodulatory properties, regulating Th1/Th2 cytokine balance and T-regulatory cell function. Poursamimi et al. (2020) reviewed saffron's immunoregulatory effects across autoimmune and non-autoimmune conditions including arthritis, inflammatory bowel disease, and atherosclerosis. Currently supported by preclinical evidence; clinical trials specifically targeting immune modulation are limited.

[17, 18]

Reproductive System

preliminary

Male reproductive health and sperm parameters

Traditional Persian medicine has long recommended saffron for male reproductive support. Tahvilzadeh et al. (2016) reviewed medicinal plants from traditional Persian medicine for sperm abnormalities, noting saffron's antioxidant properties may improve sperm motility and morphology. Evidence remains preliminary.

[21]

Energetics

Temperature

warm

Moisture

slightly dry

Taste

bitterpungentsweet

Tissue States

depression, stagnation, cold

In Unani-Tibb (Greco-Arabic) medicine, saffron is classified as warm in the 2nd degree and dry in the 1st degree (Mizaj: Haar-Khushk). Its warmth gently stimulates circulation and lifts melancholic (cold-dry) conditions. In Ayurveda, saffron (Kesar/Kumkuma) is considered tridoshic (balancing all three doshas) with a particular affinity for Vata and Kapha. It is pungent, bitter, and sweet in taste (rasa), with a sweet post-digestive effect (vipaka) and heating potency (virya). In Traditional Chinese Medicine perspective, saffron (Xi Hong Hua / Fan Hong Hua) is classified as sweet and slightly cold, entering the Heart and Liver channels, used to invigorate blood, remove stasis, and calm the spirit. Note: The TCM classification differs from the Unani system -- this reflects different theoretical frameworks applied to the same substance.

Traditional Uses

Traditional Persian Medicine (Unani-Tibb)

  • Used as a tonic for melancholia (depression associated with cold, dry temperament)
  • Applied as a uterine remedy to promote menstruation (emmenagogue)
  • Used as an aphrodisiac and male reproductive tonic
  • Applied topically mixed with milk or rosewater to brighten skin complexion
  • Used for eye diseases and to improve vision
  • Combined with opium as an analgesic and sedative

"Saffron has been a central medicinal herb in Persia for over 3,000 years. Avicenna (Ibn Sina) in the Canon of Medicine (1025 CE) described saffron as warm in the second degree and dry in the first, recommending it for melancholia, liver obstruction, and as a cardiac tonic."

[11]

Ayurveda

  • Used as Kumkuma/Kesar in formulations for depression and mental clarity
  • Applied as a complexion enhancer in milk preparations (Kesar Doodh)
  • Used as a uterine tonic in pregnancy (in very small doses with milk) to promote healthy complexion of offspring
  • Employed as a respiratory remedy for asthma and cough
  • Used in eye preparations (Anjana) for visual disorders

"In Ayurvedic tradition, saffron is considered tridoshic (balancing Vata, Pitta, and Kapha), with a sweet post-digestive effect. It is classified as Varnya (complexion-enhancing), Vishaghna (antitoxic), and Medhya (intellect-promoting)."

[11]

Traditional Chinese Medicine

  • Used as Fan Hong Hua (foreign red flower) to invigorate blood and dispel stasis
  • Applied for amenorrhea and dysmenorrhea due to blood stasis
  • Used for postpartum abdominal pain with blood stasis
  • Employed for emotional disturbance, depression, and anxiety (calming the Shen)
  • Applied for chest pain and abdominal masses

"Saffron entered Chinese materia medica relatively late compared to its Near Eastern use. It is classified as sweet and slightly cold, entering the Heart and Liver channels. Its primary action is to invigorate blood circulation and remove stasis while calming the spirit."

[11]

European Herbal Tradition

  • Used historically as a digestive stimulant and carminative
  • Applied as a remedy for melancholy and nervous disorders
  • Used as a coloring agent and flavoring in foods and medicines
  • Applied as an expectorant for respiratory conditions
  • Used in the treatment of measles and other eruptive fevers (17th-18th century)

"Culpeper (1653) wrote that saffron 'is endowed with great virtues... It is good in hysteric disorders, and useful to promote the menses.' In European herbalism, saffron was considered a warm, stimulating herb for cold, melancholic constitutions."

[11]

Modern Research

meta analysis

Meta-analysis of saffron for mild to moderate depression

Meta-analysis of randomized controlled trials evaluating saffron extract (30 mg/day) versus placebo and conventional antidepressants for the treatment of mild to moderate depression.

Findings: Saffron was significantly more effective than placebo in reducing depressive symptoms (standardized mean difference in Hamilton Depression Rating Scale scores). When compared head-to-head with conventional antidepressants (fluoxetine, imipramine, citalopram), saffron showed no significant difference in efficacy, suggesting comparable antidepressant effects with fewer reported side effects. Both stigma and petal extracts showed efficacy.

Limitations: Most included studies were conducted in Iran with relatively small sample sizes (30-60 participants). Duration of most trials was 6-8 weeks, limiting conclusions about long-term efficacy. Heterogeneity in extract standardization across studies. Potential publication bias favoring positive results.

[3]

systematic review

Systematic review of saffron for depression: mechanisms of action

Systematic review of clinical studies on saffron and depression with narrative review of antidepressant mechanisms, examining 6 RCTs with dosages, extract sources, standardization, safety profile, and treatment duration.

Findings: All six reviewed RCTs confirmed saffron's antidepressant activity at 30 mg/day. Proposed mechanisms include: serotonin reuptake inhibition by crocin and safranal; NMDA receptor modulation; anti-inflammatory activity (NF-kB inhibition); HPA axis normalization; BDNF upregulation; and antioxidant protection against neuronal damage. Saffron was well-tolerated with an adverse effect profile comparable to placebo.

Limitations: Limited number of studies (6 RCTs at time of review). All studies conducted in Iran. No studies in severe depression. Limited follow-up data on relapse rates after discontinuation.

[4]

rct

Saffron vs. methylphenidate for ADHD in children

Randomized, double-blind, 6-week pilot study comparing saffron capsules (20-30 mg/day, dose-adjusted by weight) with methylphenidate (20-30 mg/day) in 54 children aged 6-17 years with ADHD diagnosed per DSM-5 criteria.

Findings: Both saffron and methylphenidate groups showed significant improvement in Teacher and Parent ADHD Rating Scale scores from baseline. There was no statistically significant difference between groups at week 6 (P = 0.36 for parent scale; P = 0.60 for teacher scale). Frequency of adverse events was similar, though appetite suppression was more common with methylphenidate. Saffron was well-tolerated.

Limitations: Small sample (n=54). Pilot study -- not adequately powered for non-inferiority or equivalence conclusions. Short duration (6 weeks). Single-center study in Iran. No placebo arm -- cannot rule out that both groups improved due to natural course or placebo effect.

[6]

systematic review

Systematic review: saffron for neurological and psychiatric disorders

Comprehensive systematic review of RCTs evaluating saffron and its active constituents for cognition, depression, anxiety, sleep disorders, ADHD, and OCD, searching PubMed, Web of Science, and Clinical Trials databases up to June 2023.

Findings: Across 46+ identified RCTs, saffron showed significant benefits for: depression (consistent across multiple meta-analyses), anxiety (emerging evidence), cognition/Alzheimer's disease (comparable to donepezil in two trials), ADHD (comparable to methylphenidate in pilot study), and sleep quality (limited but positive data). The review confirmed saffron's favorable safety profile across all indications.

Limitations: Many included studies had small sample sizes. Majority conducted in Iran. Heterogeneity in extract preparations and standardization. Limited data on long-term use beyond 12 weeks. Few studies in severe psychiatric conditions.

[8]

rct

Affron (standardized saffron extract) for mood in non-depressed adults

Three-arm randomized, double-blind study of affron (standardized Crocus sativus extract, 28 mg/day) in 128 healthy participants self-reporting low mood but not diagnosed with clinical depression, over 4 weeks.

Findings: Affron produced a significant decrease in negative mood and symptoms related to stress and anxiety compared to placebo. Participants reported improved mood with no serious adverse effects. This study is notable for demonstrating effects in a non-clinical population, suggesting saffron may benefit subclinical mood disturbances.

Limitations: Non-clinical population (self-reported low mood, not diagnosed depression). Short duration (4 weeks). Industry-funded study (affron manufacturer). Self-report outcome measures.

[7]

meta analysis

Safety and efficacy meta-analysis for mild to moderate depression

Systematic review and meta-analysis specifically assessing both safety and efficacy of saffron for mild to moderate depression, synthesizing all available RCT data.

Findings: Saffron significantly reduced depressive symptoms compared to placebo. Safety profile was favorable, with adverse events comparable to placebo groups. No serious adverse events were attributed to saffron. The most common side effects were mild and transient (nausea, headache, decreased appetite), occurring at rates similar to placebo.

Limitations: Publication bias may overestimate effect sizes. Most studies from a single geographic region. Standardization varies between studies.

[5]

systematic review

Saffron for age-related macular degeneration

Systematic review and meta-analysis evaluating saffron supplementation for age-related macular degeneration (ARMD), analyzing neuroprotective and antioxidant effects on retinal function.

Findings: Saffron supplementation (20-30 mg/day) showed promising neuroprotective and antioxidant effects in ARMD patients. Multiple small clinical trials reported improvements in macular function (measured by electroretinography) and visual acuity. Crocin and crocetin protect retinal pigment epithelium from oxidative stress-induced damage.

Limitations: Small sample sizes across included studies. Short to moderate treatment durations. Saffron cannot replace anti-VEGF therapy for wet ARMD. More large-scale, long-term trials needed.

[9]

Preparations & Dosage

Standardized Extract

Strength: Standardized to crocin/safranal content. Typical standardization: 3.5% Lepticrosalides (affron), or 2% safranal + crocin. DER varies by manufacturer.

Capsules containing standardized saffron stigma extract. The most evidence-based preparation form. Clinical trials have used various proprietary extracts including affron (standardized to Lepticrosalides -- a combination of crocin and safranal), SaffroMood, and other products standardized to crocin/safranal content. Look for products with 3rd-party testing for purity and potency, as saffron adulteration is common.

Adult:

15-30 mg daily (most clinical trials used 30 mg/day, typically in 2 divided doses of 15 mg). For depression: 30 mg/day. For mood support: 14-28 mg/day. For ADHD (weight-adjusted in children): 20-30 mg/day.

Frequency:

Typically twice daily (morning and evening), though some products use once-daily dosing

Duration:

Clinical trials ranged from 4-22 weeks. For depression/anxiety, allow 4-6 weeks for full effect. May be used long-term; some practitioners recommend cycling (e.g., 4 weeks on, 1 week off).

Pediatric:

Children 6-17 years (ADHD indication): 20-30 mg/day based on weight, per Baziar et al. (2019). Use only under practitioner supervision.

This is the preparation form used in virtually all clinical trials and is considered the most reliable for therapeutic outcomes. Due to the high cost of genuine saffron and prevalence of adulteration, standardized extracts with independent testing are strongly preferred over raw saffron for medicinal use. ISO 3632 Grade I saffron should be the source material.

[4, 6, 7]

Infusion (Tea)

Strength: 20-30 mg dried stigma per cup (approximately 10-15 threads)

Steep 5-15 threads (approximately 20-30 mg) of high-quality dried saffron stigma in 150-200 mL of hot (not boiling) water for 10-15 minutes. The water should be approximately 70-80 degrees C. Crush or grind the threads before steeping to improve extraction. The resulting infusion should be a deep golden-yellow color.

Adult:

1 cup (150-200 mL) 1-2 times daily

Frequency:

1-2 times daily

Duration:

May be used long-term as a traditional tonic beverage

Pediatric:

Not established for children in infusion form

Traditional preparation method. The infusion extracts water-soluble crocin and picrocrocin but may not efficiently extract lipophilic safranal and crocetin. The dose per cup aligns approximately with the clinical trial dose (30 mg), but bioavailability from infusion versus standardized extract capsules has not been directly compared. Use only ISO 3632 Grade I or II saffron. Adulteration is extremely common -- look for whole threads with intact stigma shape and characteristic aroma.

[11]

Capsule / Powder

Strength: Crude dried stigma powder, 15-50 mg per capsule

Dried saffron stigma powder encapsulated. Less common than standardized extracts but available as a supplement form. Ensure product uses authenticated Crocus sativus stigma.

Adult:

30-100 mg dried saffron powder daily in divided doses

Frequency:

1-2 times daily with food

Duration:

May be used long-term

Pediatric:

Not established

Crude saffron powder may have variable potency depending on source, quality, and storage conditions. Standardized extracts are generally preferred for clinical indications. The crude powder provides the full phytochemical profile but without quantified active constituent levels.

[11]

Tincture

Strength: 1:10, 60-70% ethanol

Macerate dried saffron stigma in 60-70% ethanol at 1:10 ratio for 2-4 weeks with regular agitation. The high alcohol content ensures extraction of both hydrophilic (crocin) and lipophilic (safranal, crocetin) constituents. Filter and store in amber glass.

Adult:

0.5-2 mL (10-40 drops) twice daily

Frequency:

Twice daily

Duration:

May be used for extended periods

Pediatric:

Not established

Tincture is a traditional preparation form but is not the form used in clinical trials. The high ratio (1:10) reflects the potency of saffron -- a more concentrated tincture (1:5) would require very small doses. Provides broader extraction of both water-soluble and alcohol-soluble constituents compared to infusion alone.

[1]

Safety & Interactions

Class 1

Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)

Contraindications

relative Pregnancy (at therapeutic/high doses)

Saffron has traditional use as an emmenagogue and abortifacient at high doses. Animal studies suggest doses above 200 mg/kg may have uterotonic effects. Normal culinary doses (a pinch in cooking, approximately 1-5 mg) are considered safe in pregnancy. However, the medicinal dose (30 mg/day) should be avoided during pregnancy due to insufficient safety data and the traditional concern. The toxic dose (>5 g) can cause serious adverse effects including uterine hemorrhage.

absolute Known hypersensitivity to Crocus sativus or Iridaceae family

Allergic reactions to saffron are rare but have been reported. Cross-reactivity with other Iridaceae species is theoretically possible. Discontinue use if allergic symptoms develop.

Drug Interactions

Drug / Class Severity Mechanism
SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine, etc.) (Serotonin reuptake inhibitors) moderate Saffron has demonstrated serotonin reuptake inhibition in preclinical models. Theoretical additive serotonergic effect when combined with pharmaceutical serotonin reuptake inhibitors. However, in head-to-head clinical trials comparing saffron to fluoxetine, no serotonin syndrome-like adverse events were reported.
Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel) (Anticoagulants/antiplatelets) theoretical Some in vitro studies suggest saffron and its constituents may have antiplatelet effects. At very high doses, saffron has shown some inhibition of platelet aggregation in animal models.
Antihypertensive medications (Antihypertensives) theoretical Preclinical studies suggest saffron may have mild hypotensive effects at higher doses. Additive blood pressure lowering is theoretically possible.
Antidiabetic medications (insulin, metformin, sulfonylureas) (Hypoglycemic agents) theoretical Crocin has shown hypoglycemic effects in animal and some human studies. Additive blood glucose lowering is theoretically possible when combined with antidiabetic medications.

Pregnancy & Lactation

Pregnancy

possibly unsafe

Lactation

insufficient data

Saffron has been used traditionally as an emmenagogue and at high doses as an abortifacient. Normal culinary doses (a pinch, approximately 1-5 mg) are considered safe and are widely consumed in Iranian and Indian cuisine during pregnancy. However, the medicinal dose (30 mg/day) should be avoided during pregnancy due to the traditional uterotonic concerns and absence of modern safety data at this dose. Doses above 5 g are classified as toxic and can cause uterine hemorrhage, vomiting, bloody diarrhea, and potentially death. No data are available on saffron excretion into breast milk or effects on nursing infants at medicinal doses.

Adverse Effects

uncommon Nausea and decreased appetite — Mild GI side effects reported in some clinical trials at 30 mg/day, occurring at rates comparable to placebo. Usually transient and self-limiting.
uncommon Headache — Reported in some clinical trials at frequencies comparable to placebo groups. Not clearly dose-related at therapeutic doses.
uncommon Dry mouth — Occasionally reported in clinical trials. Mild and transient.
rare Drowsiness or sedation — Mild sedation has been reported, potentially related to safranal's GABA-A agonist activity. More commonly reported with higher doses.
very-rare Allergic reaction (skin rash, urticaria) — Rare allergic reactions have been reported. Discontinue use if allergic symptoms develop.

References

Monograph Sources

  1. [1] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press, Rochester, VT (2003) . ISBN: 978-0892817498
  2. [2] Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX (1998) . ISBN: 978-0965555500

Clinical Studies

  1. [3] Toth B, Hegyi P, Lantos T, Szakacs Z, Balint B, Rumbus Z, Garami A, Solymar M, Petervari E. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. Planta Medica (2019) ; 85 : 24-31 . DOI: 10.1055/a-0660-9565 . PMID: 30036891
  2. [4] Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human Psychopharmacology (2014) ; 29 : 517-527 . DOI: 10.1002/hup.2434 . PMID: 25384672
  3. [5] Dai L, Chen L, Wang W. Safety and Efficacy of Saffron (Crocus sativus L.) for Treating Mild to Moderate Depression: A Systematic Review and Meta-analysis. The Journal of Nervous and Mental Disease (2020) ; 208 : 269-276 . DOI: 10.1097/NMD.0000000000001118 . PMID: 32221179
  4. [6] Baziar S, Aqamolaei A, Khadem E, Mortazavi SH, Naderi S, Sahebolzamani E, Mortezaei A, Jalilevand S, Ranjbar Naeini A, Akhondzadeh S. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. Journal of Child and Adolescent Psychopharmacology (2019) ; 29 : 205-212 . DOI: 10.1089/cap.2018.0146 . PMID: 30741567
  5. [7] Kell G, Rao A, Beccaria G, Clayton P, Inber AM, Grass M. affron a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complementary Therapies in Medicine (2017) ; 33 : 58-64 . DOI: 10.1016/j.ctim.2017.06.001 . PMID: 28735826
  6. [8] Han S, Cao Y, Wu X, Li J, He J, Zhu J, Zhang S, Zhang M, Lu D, Shen Y. New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms. Phytotherapy Research (2024) ; 38 : 2025-2045 . DOI: 10.1002/ptr.8110 . PMID: 38424688
  7. [9] Shamabadi A, Asadigandomani H, Kazemzadeh K, Kord-Varkaneh H, Hosseinzadeh-Attar MJ. Saffron for Age-related Macular Degeneration: A Systematic Review and Meta-analysis. Medical Hypothesis, Discovery & Innovation Ophthalmology Journal (2024) ; 13 : 120-131 . DOI: 10.51329/mehdiophthal1505 . PMID: 39507811
  8. [10] Kehtari T, Tovar DC, Epstein D, Wright ML, De Filippis R, Nauman J, Picard D, Rosson S, Grassi G, Perna G, Iasevoli F, Cosci F, Fiedorowicz JG. From Mood to Memory: Unlocking Saffron's Potential in Brain Health. Cureus (2025) ; 17 . DOI: 10.7759/cureus.82924 . PMID: 40416274

Traditional Texts

  1. [11] Jose Bagur M, Alonso Salinas GL, Jimenez-Monreal AM, Chaouqi S, Llorens S, Martinez-Tome M, Alonso GL. Saffron: An Old Medicinal Plant and a Potential Novel Functional Food. Molecules (2017) ; 23 : 30 . DOI: 10.3390/molecules23010030 . PMID: 29295497
  2. [12] Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytotherapy Research (2018) ; 32 : 555-572 . DOI: 10.1002/ptr.6055 . PMID: 29575228

Pharmacopeias & Reviews

  1. [13] Abu-Izneid T, Rauf A, Khalil AA, Olatunde A, Khalid A, Alhumaydhi FA, Aljohani ASM, Sahab Uddin M, Heber M, Germoush MO, Al-Awthan YS, Bahattab OS, Noorani KPM, Hershan AA, Dawood Ali Shah SM. Nutritional and health beneficial properties of saffron (Crocus sativus L.): a comprehensive review. Critical Reviews in Food Science and Nutrition (2022) ; 62 : 2683-2706 . DOI: 10.1080/10408398.2020.1857682 . PMID: 33327732
  2. [14] Sani A, Tajik A, Seiiedi SS, Sani M. A review of the anti-diabetic potential of saffron. Nutrition and Metabolic Insights (2022) ; 15 . DOI: 10.1177/11786388221095223 . PMID: 35911474
  3. [15] Wang R, Hu X, Liu S, Fang Y, Chen X, Ji Z, Liang M, Dong Y, Zhang L, Wu H, Xu L. Kaempferol-3-O-sophoroside (PCS-1) contributes to modulation of depressive-like behaviour in C57BL/6J mice by activating AMPK. British Journal of Pharmacology (2024) ; 181 : 1182-1202 . DOI: 10.1111/bph.16283 . PMID: 37949672
  4. [16] Lertnimitphun P, Zhang W, Fu W, Yang B, Zheng C, Yuan M, Zhou H, Zhang X, Pei W, Lu Y, Seki H, Li S, Cao H. Safranal Alleviated OVA-Induced Asthma Model and Inhibits Mast Cell Activation. Frontiers in Immunology (2021) ; 12 . DOI: 10.3389/fimmu.2021.585595 . PMID: 34093515
  5. [17] Khazdair MR, Gholamnezhad Z, Rezaee R, Boskabady MH. A qualitative and quantitative comparison of Crocus sativus and Nigella sativa immunomodulatory effects. Biomedicine & Pharmacotherapy (2021) ; 140 . DOI: 10.1016/j.biopha.2021.111774 . PMID: 34062409
  6. [18] Poursamimi J, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohajeri SA, Ghoryani M, Mohammadi M. Crocus Sativus (Saffron): An Immunoregulatory Factor in the Autoimmune and Non-autoimmune Diseases. Iranian Journal of Allergy, Asthma, and Immunology (2020) ; 19 : 1-14 . DOI: 10.18502/ijaai.v19i(s1.r1).2852 . PMID: 32534508
  7. [19] Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clinical Medicine (2013) ; 13 : 7-12 . PMID: 23472485
  8. [20] Cicero AFG, Fogacci F, Banach M. Botanicals and phytochemicals active on cognitive decline: The clinical evidence. Pharmacological Research (2018) ; 130 : 204-212 . DOI: 10.1016/j.phrs.2017.12.029 . PMID: 29289576
  9. [21] Tahvilzadeh M, Hajimahmoodi M, Toliyat T, Karimi M, Rahimi R. An evidence-based approach to medicinal plants for the treatment of sperm abnormalities in traditional Persian medicine. Andrologia (2016) ; 48 : 860-879 . DOI: 10.1111/and.12676 . PMID: 27681644
  10. [22] Ghasemzadeh Rahbardar M, Hosseinzadeh H. Therapeutic potential of hypnotic herbal medicines: A comprehensive review. Phytotherapy Research (2024) ; 38 : 3026-3049 . DOI: 10.1002/ptr.8201 . PMID: 38595123

Last updated: 2026-03-01 | Status: published

Unlock the Full Materia Medica

This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.

No spam, ever. Unsubscribe anytime.

Full botanical illustration of Crocus sativus L.

Public domain, Köhler's Medizinal-Pflanzen (1887), Plate 194, via Wikimedia Commons